Skip to main content
Fig. 1 | Journal of Biological Engineering

Fig. 1

From: High-throughput screening of clinically approved drugs that prime nonviral gene delivery to human Mesenchymal stem cells

Fig. 1

Scatter plot showing changes in cell counts as a function of transfection priming in hAMSCs. Transfection efficiency and EGFP cell-count FCs versus Hoechst-count FCs are shown for a 445 compounds with either significant fold-increases (p < 0.05) in transfection efficiency (89 hits) or EGFP cell-count (356 hits), relative to the VC, at all four concentrations in D1 hAMSCs, b 152 compounds with either significant fold-decreases (p < 0.05) in transfection efficiency (95 hits) or EGFP cell-count (57 hits), relative to the VC, at all four concentrations in D1 hAMSCs, c 493 compounds with either significant fold-increases (p < 0.05) in transfection efficiency (150 hits) or EGFP cell-count (343 hits), relative to the VC, at all four concentrations in D2 hAMSCs, and d 192 compounds with either significant fold-decreases (p < 0.05) in transfection efficiency (114 hits) or EGFP cell-count (78 hits), relative to the VC), at all four concentrations in D2 hAMSCs

Back to article page